
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is a clinical-stage company, which inherently carries some risk due to its limited patient data. However, with the potential for new clinical data to be released later this year, there is a chance for the safety and efficacy of PBFT02 to be demonstrated, which could significantly increase market confidence and drive stock growth. Despite the inherent risk in being a clinical-stage company, Passage Bio has a strong pipeline focused on addressing critical underlying pathologies in neurodegenerative diseases, giving confidence in the company's long-term potential. Additionally, its single reportable segment allows for focused development and efficient use of resources, potentially boosting profitability in the future.
Bears say
Passage Bio is a clinical-stage biotechnology company with a single segment focused on developing and advancing genetic medicines for neurodegenerative diseases. However, their recent regulatory update requiring a randomized controlled registrational study for PBFT02 has created significant challenges and uncertainties for the company. As a result, the removal of PBFT02 from our valuation, conservative business projections, and regulatory risks have led us to downgrade PASG to Neutral with a 12-month PT of $23, reflecting a 66% downside potential.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares